# Longevity Consortium

> **NIH NIH U19** · TRANSLATIONAL GENOMICS RESEARCH INST · 2024 · $8,963,414

## Abstract

Overall Summary
The processes contributing to human aging, age-related diseases (e.g., Alzheimer’s disease and related
dementias; ADRD), and longevity are notoriously complex and multifactorial. This complexity makes it difficult to
identify longevity-promoting (i.e. geroprotective) interventions and targets, clinically useful biomarkers, and
predictive models that could enhance human health. One strategy to overcome this is to assess the findings of
one study in the light of findings from studies with different designs or foci – i.e., integrate or ‘triangulate’ those
findings – such as cell models, cross species studies and human association studies. Such integration could
lead to further validation of individual findings and put into context any one or group of such findings. The LC will
embark on an unprecedented level of integration by capitalizing on its legacy findings and 20+ year history,
network of investigators, expanded data sharing capabilities, unique resources, and assay capabilities, and
pursue 5 projects (P1-P5) taking different approaches. Each is designed to address a specific overarching
objective of the RFA and contribute data and results for use in integrated analyses. In addition, an Integrated
Analysis Core (IAC) and an Administrative Core (AC) will be developed to address further objectives in the RFA.
The five projects are rooted in research efforts and discoveries in the last LC funding cycle: P1 will study diverse
human populations to determine the contexts within which longevity-related factors exhibit associations; P2 will
study genomically-mediated evolutionary processes contributing to longevity; P3 will study extreme longevity
(EL) and its relationship to ADRD in diverse human populations; P4 will study aging rate indicators in response
to candidate geroprotective drugs in mice; and P5 will explore novel cell systems and constructs derived from
individuals with EL and other longevity related phenotypes. The IAC will seek to integrate results and data across
these projects by developing appropriate infrastructure and analytical methods, as well as engaging in analyses
with the research teams pursuing each project. The AC will oversee and track progress of the research as well
as monitor financial and related activities. The LC will also work with the NIA-funded Data Management and
Coordinating Center (DMCC) and its Exceptional Longevity Translational Resources (ELITE) internet data portal
to enable broader access to LC data. Working groups will enhance specific activities, e.g., data sharing and
training, and, importantly, a Pharmaceutical and Translational Advisory Panel (PTAP) will be established to
enable discussions about the best way to follow up findings in drug development contexts. The LC will identify
compelling and verified insights into human longevity based on the proposed studies and its expansive integrated
approach and ultimately identify novel vetted candidate pre-clinical drug targets, geroprotectiv...

## Key facts

- **NIH application ID:** 11022974
- **Project number:** 2U19AG023122-16
- **Recipient organization:** TRANSLATIONAL GENOMICS RESEARCH INST
- **Principal Investigator:** Thomas Girke
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $8,963,414
- **Award type:** 2
- **Project period:** 2004-09-30 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11022974

## Citation

> US National Institutes of Health, RePORTER application 11022974, Longevity Consortium (2U19AG023122-16). Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/grant/nih/11022974. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*